Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
France Sets July Deadline for Medical Cannabis Regulations as Withheld Study Shows …
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
7 unexpected takeaways from the newest research on cannabis and brain effects
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products to Schedule III
The DEA rescheduling cannabis products from Schedule I to Schedule III marks a pivotal regulatory change. This shift applies to FDA-approved cannabis-derived medications, easing prescribing and research barriers. Clinicians should note this change…
Relationships between cannabis use and mental disorders: assessing the coherence of …
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Schedules of Controlled Substances: DEA Update on Synthetic Cannabinoids
The DEA synthetic cannabinoids schedule I placement update designates cumyl-pegaclone as a high-risk substance with no accepted medical use. This update highlights ongoing challenges in regulating novel synthetic cannabinoids. Clinicians should be aware…
Fewer Employees Skip Work Days Where Medical Marijuana Is Legal, Especially For …
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Mixed Cannabis Industry Articles June 18 2026 Overview
This post covers mixed cannabis industry articles June 18 2026, featuring 37 cannabis articles scored below the clinical relevance threshold. Summaries and source links are included for detailed review. Stay informed on the latest mixed cannabis industry…
